Clinical Trials Logo

ROS1 Gene Mutation clinical trials

View clinical trials related to ROS1 Gene Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04322890 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

PIKACHU
Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

NCT ID: NCT04042558 Recruiting - NSCLC Stage IV Clinical Trials

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

GFPC 06-2018
Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

NCT ID: NCT03994796 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Start date: August 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.